Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension

20131,365 citationsJournal Articlebronze Open Access

Authors

Hossein Ardeschir Ghofrani · Justus-Liebig-Universität Gießen

Andrea Maria D’Armini · University of Pavia

Friedrich Grimminger · German Center for Lung Research

Marius M. Hoeper · Medizinische Hochschule Hannover

Pavel Jansa · General University Hospital in Prague

Nick H. Kim · University of California San Diego

Eckhard Mayer

Abstract

Riociguat significantly improved exercise capacity and pulmonary vascular resistance in patients with chronic thromboembolic pulmonary hypertension. (Funded by Bayer HealthCare; CHEST-1 and CHEST-2 ClinicalTrials.gov numbers, NCT00855465 and NCT00910429, respectively.)

Topics & Keywords

Pulmonary Hypertension Research and Treatments Heart Failure Treatment and Management Cardiovascular Issues in Pregnancy

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 369, Issue 4, pp. 319-329

DOI: 10.1056/nejmoa1209657

Field-Weighted Citation Impact: 92.17